Ultragenyx Pharma (RARE) Misses Q1 EPS by 6c

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.35), $0.06 worse than the analyst estimate of ($1.29).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) PT Lowered to $25 at H.C. Wainwright
• Asana shares tumble on weak third quarter earnings outlook
• Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance